Bioprocessing

New Drug May Stop Alzheimer's Before Symptoms Appear
Research & Development New Drug May Stop Alzheimer's Before Symptoms Appear

Long before a name is forgotten or a memory fades, a silent war is waged within the brain, and a new pharmaceutical weapon may have just arrived to fight it on its own terms. This battleground, previously invisible, is now the focus of groundbreaking research from Northwestern University, where

Urinary MicroRNA Aging Clock – Review
Research & Development Urinary MicroRNA Aging Clock – Review

The longstanding quest to measure the true pace of human aging, independent of the calendar, has taken a decisive turn with the development of a biomarker that can be read from a simple urine sample. The development of the urinary microRNA (uEV-miRNA) aging clock represents a significant

Targeted Integration Accelerates Biologic Drug Timelines
Biotech & Bioprocessing Targeted Integration Accelerates Biologic Drug Timelines

The intricate dance of cellular machinery required to produce life-saving biologic therapies has long been dictated by a rhythm of chance, but a new era of genomic precision is fundamentally changing the tempo of drug development. For decades, the biopharmaceutical industry has grappled with a

Data Reveals Top Causes of Biopharma Batch Failures
Biotech & Bioprocessing Data Reveals Top Causes of Biopharma Batch Failures

In the high-stakes world of biopharmaceutical manufacturing, where a single production run can be valued in the millions of dollars, the quiet disposal of a failed batch represents a catastrophic loss of resources, time, and patient trust. While the industry strives for perfection, the reality is

Omisirge Approval Redefines Cell Therapy Standards
Biotech & Bioprocessing Omisirge Approval Redefines Cell Therapy Standards

The body's intricate system for manufacturing blood cells is a marvel of biological engineering, but when this internal factory fails, the consequences are catastrophic, leaving patients defenseless against infection and uncontrolled bleeding. For individuals diagnosed with severe aplastic anemia

FDA Approves First CAR-T Therapy for Marginal Zone Lymphoma
Biotech & Bioprocessing FDA Approves First CAR-T Therapy for Marginal Zone Lymphoma

Imagine a landscape where a rare cancer, often resistant to repeated treatments, finally meets a game-changing solution. On December 4, this became reality as the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel, marketed as Breyanzi by Juno Therapeutics, as the first

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later